SYF2

SYF2 (p29/NTC31) is a conserved subunit of the Prp19C/NTC spliceosome-associated complex that links pre-mRNA splicing and alternative splicing to downstream gene-expression and cell-cycle programs (PMID:31943118, PMID:38627018). In yeast, Syf2 is required for full Prp19C occupancy at transcribed genes and for the Prp19C–TREX interaction, thereby coupling transcription elongation to nuclear mRNA export, with overlapping function shared with Cwc15 (PMID:38627018). In mammalian cells SYF2 directs alternative splicing programs, associating with ECT2 pre-mRNA and driving ECT2 exon 5 inclusion, a program convergent with ZRANB2 (PMID:31943118). SYF2 is essential for embryonic viability, with loss causing early lethality, reduced Chk1 and α-tubulin mRNA levels, and an aberrant DNA damage checkpoint response (PMID:22448250). Across cancer and developmental contexts SYF2 promotes G1/S cell-cycle progression (PMID:31943118, PMID:22448250), and its suppression alleviates TDP-43 aggregation, mislocalization, and neurodegeneration in ALS models (PMID:36736291). SYF2 is post-transcriptionally repressed through direct 3'-UTR targeting by miR-376c-3p and miR-621 (PMID:31522605, PMID:32417187).

1. 2012 High

   Established that SYF2 is essential in vivo and functionally couples post-transcriptional control of Chk1/α-tubulin to the DNA damage checkpoint, moving it beyond a presumed splicing factor to a developmentally required regulator.

   Evidence Gene-trap knockout mouse with transgenic rescue, zebrafish morpholino knockdown, RT-qPCR and aphidicolin/UV checkpoint assays

   PMID:22448250

   Open questions at the time

   • Direct molecular mechanism linking SYF2 to Chk1/α-tubulin mRNA stability not resolved
   • Whether the checkpoint defect is a direct splicing consequence or indirect is unclear
2. 2013 Low

   Linked SYF2 expression to glial/neuronal injury responses, raising a role in neuroinflammation beyond constitutive cell-cycle function.

   Evidence siRNA knockdown in C6 astrocyte and PC12 neuronal cell lines, conditioned-media apoptosis assay, LPS rat model

   PMID:24301298

   Open questions at the time

   • No mechanistic pathway placement beyond cellular phenotype
   • No rescue experiment
3. 2014 Low

   Multiple cancer/neural systems converged on SYF2 as a driver of G1/S progression, implicating cyclin D1 and p21 as affected nodes and microtubule dynamics in Schwann cell migration.

   Evidence siRNA knockdown with flow cytometry and Western blot (p21, PCNA, cyclin D1) in A549 and U87 cells; siRNA plus microtubule imaging and migration assay in primary Schwann cells with sciatic nerve injury model

   PMID:24962097 PMID:24985881 PMID:25433998

   Open questions at the time

   • Single siRNA approaches without rescue
   • Whether cyclin D1/p21/microtubule effects are direct splicing targets unknown
4. 2019 Low

   Identified SYF2 as a post-transcriptionally regulated target, with miR-376c-3p directly binding its 3'-UTR to repress proliferation and migration.

   Evidence Luciferase 3'-UTR reporter assay, overexpression/knockdown, proliferation and migration assays in gastric cancer cells

   PMID:31522605

   Open questions at the time

   • No deep mechanistic characterization of SYF2 downstream function
   • Single lab
5. 2020 Medium

   Connected SYF2's splicing activity to a defined alternative splicing program (ECT2 exon 5 inclusion) and to chemotherapy resistance, defining a mechanistic output of SYF2 in cancer cells; a second study confirmed miR-621 as an additional 3'-UTR repressor.

   Evidence RNAi screen, RNA-seq, RIP showing SYF2–ECT2 pre-mRNA association, cell-cycle analysis (idx 0); luciferase 3'-UTR reporter and xenograft rescue (idx 8)

   PMID:31943118 PMID:32417187

   Open questions at the time

   • Direct splice-site contacts of SYF2 not mapped
   • How ECT2-Ex5+ inclusion mediates doxorubicin resistance not fully defined
6. 2023 Medium

   Showed that lowering SYF2 is protective in disease, alleviating TDP-43 pathology and neurodegeneration across multiple ALS models, establishing SYF2 as a disease modifier.

   Evidence RNAi/genetic suppression in C9ORF72 and sporadic ALS patient-derived neurons, TDP-43 mouse loss-of-function, perturbational bioinformatics

   PMID:36736291

   Open questions at the time

   • Mechanism connecting SYF2 splicing function to TDP-43 aggregation unresolved
   • Whether protection is splicing-dependent unknown
7. 2024 Medium

   Mechanistically placed Syf2 within Prp19C, showing it is required for Prp19C occupancy at genes and for the Prp19C–TREX interaction, thereby coupling transcription elongation to mRNA export.

   Evidence ChIP for Prp19C/TREX occupancy, Co-IP for Prp19C–TREX interaction, Δsyf2/Δcwc15 genetic epistasis, transcription elongation assays in yeast

   PMID:38627018

   Open questions at the time

   • Conservation of the Prp19C–TREX coupling role in mammals not demonstrated
   • Structural basis of Syf2's contribution to Prp19C occupancy unknown

• How SYF2's core role in Prp19C-dependent splicing and transcription–export coupling mechanistically produces its specific phenotypic outputs — checkpoint regulation, G1/S progression, and TDP-43 protection — remains unresolved.
• No direct link between splicing activity and Chk1/α-tubulin/cyclin D1 regulation
• Mammalian Prp19C–TREX coupling untested
• Mechanism of TDP-43 rescue undefined